Walid Macaron, MD MSc

Our new review explores how the definition of high-risk Ph+ ALL is shifting across tx eras. Risk is dynamic, shaped by the interplay of biology, response, and treatment context. We examine key determinants, their evolving relevance, and risk-adapted strategies in the current era.

Check out our most recent publication in @BloodCancerJnl evaluating the prognostic impact of early NGS-based MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. nature.com/articles/s41408-0… @NicholasShortMD @DrHKantarjian #Leusm #ALLsm

An incredible experience presenting our work at #ASH24! Truly grateful for the guidance and support from the best mentor @NicholasShortMD.

Check out our latest publication in @AjHematology: onlinelibrary.wiley.com/doi/… We assessed MRD by high-sensitivity NGS-based assay for IG/TCR vs. standard of care PCR for BCR::ABL1 in patients with newly diagnosed Ph+ ALL. #ALLsm @NicholasShortMD @DrHKantarjian @MDAndersonNews

Absolutely thrilled to have matched at @BCM_InternalMed in Internal Medicine Residency!!!! #Match2023 – at Houston, TX

Unreal feeling. #Match2023

First #ASH22 meeting experience was beyond amazing!!🩸 I am humbled and thankful for the opportunity to present my poster, and first oral presentation. Sincerely grateful for the support and guidance from @NicholasShortMD & Dr Jabbour, and the incredible team at @MDAndersonNews.

I am honored to receive the Abstract Achievement Award for our selected oral presentation at this year’s @ASH_hematology meeting. #ASH22 Grateful for the mentorship @NicholasShortMD @DrHKantarjian and the incredible leukemia team at @MDAndersonNews. See you in #NOLA!! #ASH2022

Excellent talks by @MDAndersonNews Leukemia experts Pr. Jabbour, @NicholasShortMD, and @FadiHaddad_MD on ALL #ALLsm #Leusm. #SOHO22

Hello #MedTwitter! I am Walid Macaron, an IMG from Lebanon 🇱🇧, currently doing research at @MDAndersonNews. I'm happy to be applying to #InternalMedicine for #Match2023. Looking forward to an exciting application season! #InsideTheMatch

Our latest pub. in @AjHematology found very poor outcomes in pts with AML who experience MRD recurrence. Data suggest that serial MRD monitoring is crucial & may allow for early ident. of pts w/impending relapse, who may benefit from Tx change/SCT. @NicholasShortMD @DrHKantarjian

Check out our abstract for the upcoming #EHA2022 on outcomes of patients with R/R B-cell ALL after failure of both INO and Blinatumomab. Looking forward to sharing our poster presentation! @NicholasShortMD @MDAndersonNews @EHA_Hematology library.ehaweb.org/eha/2022/…